Medical/Pharmaceuticals
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will evaluate the safety and preliminary efficacy of ATG-031 in patients withadvanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). * ATG-031, discovered and developed in-house by Antengene, is t...
2023-12-11 08:30
1358
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published inThe Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Ex...
2023-12-10 18:00
1362
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
* This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations. * This analysis shows a clinically meaningful improvement in progression-free survivala...
2023-12-08 23:13
3342
Whole Exome Sequencing Advancements in Unraveling Rare Diseases in Japan
TOKYO, Dec. 8, 2023 /PRNewswire/ -- According to Estimation of the Number of
Patients With Mitochondrial Diseases: A Descriptive Study Using in a nationwide
database inJapan
2023-12-08 13:40
1658
PharmaBlock Officially Joins United Nations Global Compact
NANJING, China, Dec. 8, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has officially joined the United Nations Global Compact (UNGC), which not only affi...
2023-12-08 12:37
1272
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. * This marks the 13th NDA approval obtained by CSt...
2023-12-08 12:10
4952
CU Medicine study published in The Lancet Infectious Diseases concludes that a novel oral microencapsulated live bacteria consortia (SIM01) alleviates long COVID symptoms
HONG KONG, Dec. 8, 2023 /PRNewswire/ -- A randomised, double-blind, placebo-controlled trial (RECOVERY STUDY) conducted by TheChinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and Microbiota I-Center (MagIC) showed that an oral microbiome microencapsulated formula (SIM01)...
2023-12-08 10:38
1813
Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals
GEMBLOUX, Belgium, Dec. 7, 2023 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the construction of its new Good Manufacturing Practices (GMP) compliant manufacturing facility in Gembloux,Belgium, for radiopharmaceuticals. ...
2023-12-08 10:00
1251
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy
* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. * Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and ...
2023-12-08 07:39
1491
2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer
NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 202...
2023-12-07 21:00
1211
Unlocking the Potential of Multi-Omics in Precision Medicine: A Conversation with Kazusa DNA Research Institute
CHIBA, Japan, Dec. 7, 2023 /PRNewswire/ -- The integration of multi-omics approaches offers a comprehensive panorama for advancing our comprehension of biology. It now plays a more important role in understanding the roots of diseases, and in expediting precision medicine and catalyzing advanceme...
2023-12-07 15:37
1600
Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support
HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the man...
2023-12-07 10:00
1636
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
ROCKVILLE, M.D. and SUZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-12-07 09:00
3122
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imag...
2023-12-07 06:45
1426
World Innovation Summit for Health Announces Dates for 2024 Event and Strategic Partnership with WHO
Health leaders to prepare report on the protection of health in armed conflict. DOHA, Qatar, Dec. 7, 2023 /PRNewswire/ -- The World Innovation Summit for Health (WISH), an initiative of Qatar Foundation for Education, Science and Community Development (QF), announced the WISH 2024 summit will ta...
2023-12-07 03:00
1779
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
ANDERNACH, Germany, Dec. 6, 2023 /PRNewswire/ -- LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), ...
2023-12-06 23:00
1509
GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in
accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://www.ipeace.com
2023-12-06 22:30
1211
Micro Medical Solutions Announces Completion of Enrollment in the STAND Pivotal Clinical Trial
Clinical investigators complete enrollment in the 177 patient, randomized, controlled study, STAND (A Clinical Evaluation of the MicroSTent PeripherAl Vascular SteNt in subjects with Arterial Disease Below the Knee, NCT03477604). WILMINGTON, Mass., Dec. 6, 2023 /PRNewswire/ -- Micro Medical Solut...
2023-12-06 21:32
1632
SaniSure earns EcoVadis Silver Rating, recognizing strong commitment to sustainability
CAMARILLO, Calif., Dec. 6, 2023 /PRNewswire/ -- SaniSure, a global player in single-use bioprocessing solutions (drug substance and drug product form & fill) and cell & gene therapy is proud to announce that it has been awarded the EcoVadis Silver Rating for its sustainability practices. This rec...
2023-12-06 20:30
1723
WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader
SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at its first standalone CDMO site in Suzhou,China. The audit m...
2023-12-06 17:00
1335
Week's Top Stories
Most Reposted
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 319 media titles]
2024-05-08 14:37
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 318 media titles]
2024-05-07 08:00
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 310 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 297 media titles]
2024-05-08 16:44
Thousands set to gather in Singapore for Rotary's international convention, the Garden City's largest association event post-pandemic
[Picked up by 285 media titles]
2024-05-09 11:00
Most Read
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
2024-05-08 14:37
6606
IN2MF in Kuala Lumpur Presented by Bank Indonesia
2024-05-08 16:44
6433